134 related articles for article (PubMed ID: 19261353)
1. Role of antibodies in controlling dengue virus infection.
van der Schaar HM; Wilschut JC; Smit JM
Immunobiology; 2009; 214(7):613-29. PubMed ID: 19261353
[TBL] [Abstract][Full Text] [Related]
2. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.
Goncalvez AP; Engle RE; St Claire M; Purcell RH; Lai CJ
Proc Natl Acad Sci U S A; 2007 May; 104(22):9422-7. PubMed ID: 17517625
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Dependent Dengue Virus Entry Modulates Cell Intrinsic Responses for Enhanced Infection.
Chan CYY; Low JZH; Gan ES; Ong EZ; Zhang SL; Tan HC; Chai X; Ghosh S; Ooi EE; Chan KR
mSphere; 2019 Sep; 4(5):. PubMed ID: 31533998
[TBL] [Abstract][Full Text] [Related]
5. Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection.
Moi ML; Takasaki T; Saijo M; Kurane I
Trans R Soc Trop Med Hyg; 2013 Jan; 107(1):51-8. PubMed ID: 23296697
[TBL] [Abstract][Full Text] [Related]
6. Antibody-dependent enhancement of dengue virus infection is inhibited by SA-17, a doxorubicin derivative.
Ayala-Nuñez NV; Jarupathirun P; Kaptein SJ; Neyts J; Smit JM
Antiviral Res; 2013 Oct; 100(1):238-45. PubMed ID: 23994499
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies.
Wu RS; Chan KR; Tan HC; Chow A; Allen JC; Ooi EE
Antiviral Res; 2012 Dec; 96(3):340-3. PubMed ID: 23041143
[TBL] [Abstract][Full Text] [Related]
8. The serotype-independent but concentration-dependent enhancing antibodies among Thai dengue patients.
Teerasut C; Lei HY; Natthakorn K; Jittmittraphap A; Thammapalo S; Witayathawornwong P; Lin YT; Jarman RG; Sawanpanyalert P; Jampangern W; Limkittikul K
Southeast Asian J Trop Med Public Health; 2012 May; 43(3):624-33. PubMed ID: 23077841
[TBL] [Abstract][Full Text] [Related]
9. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
Guy B; Chanthavanich P; Gimenez S; Sirivichayakul C; Sabchareon A; Begue S; Yoksan S; Luxemburger C; Lang J
Vaccine; 2004 Sep; 22(27-28):3563-74. PubMed ID: 15315835
[TBL] [Abstract][Full Text] [Related]
10. Evaluation and analysis of dengue virus enhancing and neutralizing activities using simple high-throughput assays.
Li XQ; Chen J; Huang YF; Ding XX; Liu LD; Qiu LW; Pan YX; Deng YQ; Hu DM; Di B; Qin CF; Che XY
Appl Microbiol Biotechnol; 2013 Jul; 97(14):6503-11. PubMed ID: 23760532
[TBL] [Abstract][Full Text] [Related]
11. Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans.
Flipse J; Wilschut J; Smit JM
Traffic; 2013 Jan; 14(1):25-35. PubMed ID: 22998156
[TBL] [Abstract][Full Text] [Related]
12. Early dengue virus interactions: the role of dendritic cells during infection.
Santos Souza HF; da Silva Almeida B; Boscardin SB
Virus Res; 2016 Sep; 223():88-98. PubMed ID: 27381061
[TBL] [Abstract][Full Text] [Related]
13. Approaches to Interrogating the Human Memory B-Cell and Memory-Derived Antibody Repertoire Following Dengue Virus Infection.
Lyski ZL; Messer WB
Front Immunol; 2019; 10():1276. PubMed ID: 31244836
[TBL] [Abstract][Full Text] [Related]
14. Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection.
Mukherjee S; Pierson TC; Dowd KA
Methods Mol Biol; 2014; 1138():75-97. PubMed ID: 24696332
[TBL] [Abstract][Full Text] [Related]
15. Dengue virus isolation relying on antibody-dependent enhancement mechanism using FcγR-expressing BHK cells and a monoclonal antibody with infection-enhancing capacity.
Moi ML; Lim CK; Tajima S; Kotaki A; Saijo M; Takasaki T; Kurane I
J Clin Virol; 2011 Nov; 52(3):225-30. PubMed ID: 21824813
[TBL] [Abstract][Full Text] [Related]
16. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.
Lisova O; Belkadi L; Bedouelle H
J Mol Recognit; 2014 Apr; 27(4):205-14. PubMed ID: 24591178
[TBL] [Abstract][Full Text] [Related]
17. Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models.
Tang WW; Grewal R; Shresta S
Curr Opin Virol; 2015 Aug; 13():61-6. PubMed ID: 26001278
[TBL] [Abstract][Full Text] [Related]
18. Blockade of dengue virus entry into myeloid cells by endocytic inhibitors in the presence or absence of antibodies.
Carro AC; Piccini LE; Damonte EB
PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006685. PubMed ID: 30092029
[TBL] [Abstract][Full Text] [Related]
19. Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus.
Ito M; Mukai RZ; Takasaki T; Kotaki A; Kurane I
Arch Virol; 2010 Oct; 155(10):1617-24. PubMed ID: 20644969
[TBL] [Abstract][Full Text] [Related]
20. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection.
Setthapramote C; Sasaki T; Puiprom O; Limkittikul K; Pitaksajjakul P; Pipattanaboon C; Sasayama M; Leuangwutiwong P; Phumratanaprapin W; Chamnachanan S; Kusolsuk T; Jittmittraphap A; Asai A; Arias JF; Hirai I; Kuhara M; Okuno Y; Kurosu T; Ramasoota P; Ikuta K
Biochem Biophys Res Commun; 2012 Jul; 423(4):867-72. PubMed ID: 22713454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
